INmune Bio Q1 net loss narrows to $9.7M; Alzheimer's Phase 2 data expected late June

Inmune Bio, Inc.

2025-Q1 EPS reported -$0.43 vs consensus -$0.48 ▲ beat (+10.3%)

Net loss $9.7M ($0.42 per share) vs $11.0M YoY; R&D expenses down to $7.6M from $8.7M.
Cash $19.3M at March 31; raised $2.1M post-quarter via stock sale; 23.2M shares outstanding.
Top-line results from Phase 2 Alzheimer's trial (MINDFuL) expected in second half of June.
Plans to file BLA for CORDStrom in RDEB in early 2026; partnered with Catapult for manufacturing scale-up.
INKmune Phase I completed, Phase II opened; safety endpoint met; trial expanded to VA Health System.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.